Biomarker studies have revealed some genomic signatures in tumor biopsies that are predictive of the efficacy and outcomes of ICIs, including positive PD-L1 expression, high tumor mutational burden (TMB), mismatch repair status, T-effect or interferon gamma gene signatures, and T-cell infiltration status (4–8). The gene discussed is IFNG; the disease is neoplasm.